

Dolutegravir /lamivudine/ tenofovir disoproxil fumarate  
50 mg/ 300 mg/ 300 mg tablets  
(Macleods Pharmaceuticals Limited), HA713

WHOPAR Part 2

June 2022  
updated February 2026


### All accepted presentations

See:

<https://extranet.who.int/pqweb/medicines/prequalified-lists/finished-pharmaceutical-products>

Search for WHO reference number (as provided in the header).

### Appearance of [HA713 trade name]\*



---

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.  
Page 1 of 1